Abilify approved for bipolar adolescents
Executive Summary
Bristol-Myers Squibb and Otsuka Pharmaceutical's Abilify (aripiprazole) wins approval for the acute treatment of manic and mixed episodes associated with bipolar I disorder, with or without psychotic features, in patients 10 to 17 years old, the firms announce Feb. 29. The approval provides clinicians with expanded treatment options for pediatric patients with bipolar I disorder, following approval in August for Johnson & Johnson's Risperdal (risperidone) for that age group. Last November, Bristol/Otsuka's dopamine partial agonist, which was already indicated for treatment of bipolar I disorder and schizophrenia, won approval for treatment of schizophrenia in adolescents (1"The Pink Sheet" Feb. 4, 2008, p. 10)
You may also be interested in...
Bristol Readies Abilify Sales Force For Major Depressive Disorder Push
Bristol-Myers Squibb has restructured its sales force to support the launch of its atypical antipsychotic Abilify as an adjunct treatment for adults with major depressive disorder, Worldwide Pharmaceuticals Chief Operating Officer Lamberto Andreotti said during the company's 2007 fourth-quarter earnings call Jan. 31
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.